BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Short Interest Up 5.6% in March

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) was the recipient of a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 32,250,000 shares, an increase of 5.6% from the March 15th total of 30,550,000 shares. Based on an average trading volume of 3,290,000 shares, the short-interest ratio is presently 9.8 days.

BioCryst Pharmaceuticals Stock Down 1.3 %

Shares of NASDAQ BCRX opened at $4.61 on Wednesday. The firm has a market cap of $950.35 million, a PE ratio of -3.91 and a beta of 1.90. The business has a 50 day moving average price of $5.27 and a two-hundred day moving average price of $5.63. BioCryst Pharmaceuticals has a fifty-two week low of $4.45 and a fifty-two week high of $9.06.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Monday, February 26th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04). The firm had revenue of $93.40 million for the quarter, compared to analyst estimates of $89.19 million. On average, analysts anticipate that BioCryst Pharmaceuticals will post -0.68 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC reaffirmed a “buy” rating and set a $12.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Wednesday, April 10th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, BioCryst Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $13.29.

Institutional Trading of BioCryst Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of BCRX. Legal & General Group Plc increased its holdings in shares of BioCryst Pharmaceuticals by 0.9% in the 4th quarter. Legal & General Group Plc now owns 164,868 shares of the biotechnology company’s stock valued at $1,893,000 after acquiring an additional 1,415 shares during the last quarter. Commonwealth Equity Services LLC boosted its holdings in BioCryst Pharmaceuticals by 0.9% in the second quarter. Commonwealth Equity Services LLC now owns 162,084 shares of the biotechnology company’s stock worth $1,141,000 after purchasing an additional 1,485 shares during the period. Advisory Services Network LLC increased its stake in BioCryst Pharmaceuticals by 46.3% during the first quarter. Advisory Services Network LLC now owns 4,740 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 1,500 shares during the last quarter. Diversified Trust Co raised its holdings in shares of BioCryst Pharmaceuticals by 10.6% during the third quarter. Diversified Trust Co now owns 20,978 shares of the biotechnology company’s stock worth $149,000 after purchasing an additional 2,004 shares during the period. Finally, Fairfield Bush & CO. bought a new position in shares of BioCryst Pharmaceuticals in the 1st quarter worth about $34,000. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.